Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.

Emanuela M. Ghia, PhD, Laura Z. Rassenti, PhD, George F. Widhopf, PhD, Gregg J. Silverman, MD, Donna S. Neuberg, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, John G. Gribben, MD, Jennifer R. Brown, MD, PhD, Kanti R. Rai, MD, John C. Byrd, MD, Neil E. Kay, MD, Andrew W. Greaves, BS, Thomas J. Kipps, MD, PhD

Blood (2007) 110 (11): 740.

https://doi.org/10.1182/blood.V110.11.740.740

Published: 2007

Journal Articles

Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.

Laura Z. Rassenti, PhD, Donna S. Neuberg, PhD, Lang Huynh, B.S., William G. Wierda, MD,PhD, John G. Gribben, MD, Jennifer R. Brown, MD,PhD, Ian W. Flinn, MD,PhD, Kanti R. Rai, MD, John C. Byrd, MD, Neil E. Kay, MD, Andrew W. Greaves, B.S., Thomas J. Kipps, MD,PhD

Blood (2006) 108 (11): 2778.

https://doi.org/10.1182/blood.V108.11.2778.2778

Published: 2006

Journal Articles

Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.

Michael R. Grever, MD, David M. Lucas, PhD, Gordon W. Dewald, PhD, Donna S. Neuberg, PhD, Ian W. Flinn, MD, PhD, Martin S. Tallman, MD, John G. Gribben, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3487.

https://doi.org/10.1182/blood.V104.11.3487.3487

Published: 2004

Journal Articles

Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.

David M. Lucas, PhD, Gordon W. Dewald, PhD, Donna S. Neuberg, PhD, John C. Byrd, MD, Gerard Lozanski, MD, Jennifer Harbison, Kammy D. Cunningham, Ian W. Flinn, MD, PhD, Martin S. Tallman, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 949.

https://doi.org/10.1182/blood.V104.11.949.949

Published: 2004

Journal Articles

Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.

Shinichi Kitada, PhD, John C. Reed, MD PhD, David M. Lucas, PhD, Donna S. Neuberg, PhD, John G. Gribben, MD, Gordon W. Dewald, PhD, Ian W. Flinn, MD PhD, Martin S. Tallman, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 956.

https://doi.org/10.1182/blood.V104.11.956.956

Published: 2004

NARROW

Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.

Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.

Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.

Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.

Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.

Email alerts

ASH Publications

American Society of Hematology

Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.

Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.

Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.

Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.

Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only